Clinical Effectiveness and Pharmacokinetics of Dalbavancin in Treatment-Experienced Patients with Skin, Osteoarticular, or Vascular Infections

Dalbavancin (DBV) is a lipoglycopeptide approved for the treatment of Gram-positive infections of the skin and skin-associated structures (ABSSSIs). Currently, its off-label use at different dosages for other infections deserves attention. This work aimed to study the clinical effectiveness and tole...

Descripción completa

Detalles Bibliográficos
Autores principales: Stroffolini, Giacomo, De Nicolò, Amedeo, Gaviraghi, Alberto, Mula, Jacopo, Cariti, Giuseppe, Scabini, Silvia, Manca, Alessandra, Cusato, Jessica, Corcione, Silvia, Bonora, Stefano, Di Perri, Giovanni, De Rosa, Francesco Giuseppe, D’Avolio, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501058/
https://www.ncbi.nlm.nih.gov/pubmed/36145630
http://dx.doi.org/10.3390/pharmaceutics14091882

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501058/
https://www.ncbi.nlm.nih.gov/pubmed/36145630
http://dx.doi.org/10.3390/pharmaceutics14091882

Ejemplares similares